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This study aimed to review the evidence for the use of long-term oxygen therapy for patients with chronic
obstructive pulmonary disease (COPD).
The design was a systematic Cochrane review of randomized controlled trials (RCTs) of long-term oxygen
therapy for COPD and main outcome measure was survival on home oxygen therapy.
Five RCTs were identified. Data from two trials of nocturnal oxygen therapy in mild to moderate hypoxaemia
were aggregated. Data from the other three trials could not be aggregated because of differences in trial design and
patient selection. Treatment with continuous versus nocturnal oxygen therapy produced a significant improvement
in mortality after 24 months [Peto odds ratio 0?45, 95% confidence interval (95% CI) 0?25–0?81] for the continuous
therapy group. Treatment with oxygen therapy versus no oxygen therapy showed a significant improvement in
mortality after five years in the group receiving oxygen therapy (Peto odds ratio 0?42, 95% CI 0?18–0?98). There
was no difference in mortality for patients with COPD and mild to moderate daytime hypoxaemia and nocturnal
desaturation receiving nocturnal oxygen therapy versus no oxygen therapy or sham treatment. Long-term oxygen
therapy versus no oxygen therapy in patients with COPD and moderate hypoxaemia had no effect on survival.
In conclusion, long-term oxygen therapy improved survival in a selected group of COPD patients with severe
hypoxaemia but few co-morbidities. Long-term oxygen therapy did not improve survival in patients with moderate
hypoxaemia or in those with mild to moderate hypoxaemia and arterial desaturation at night.
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Patients with chronic obstructive pulmonary disease
(COPD) develop chronic hypoxaemia which is related to
the progression of their underlying lung condition. Over the
last 20 years domiciliary long-term oxygen therapy (LTOT)
has become one of the major forms of treatment for
hypoxaemic COPD patients. A frequently held clinical
belief exists, from early studies in the United Kingdom, that
LTOT will give COPD patients an additional 5 years of
life (1).
To determine the effect of domiciliary oxygen therapy on
the survival and quality of life of patients with COPD and
hypoxaemia we conducted a systematic Cochrane review of
randomized controlled trials (RCTs).Received 17 August 2000 and accepted in revised form 23 February
2001.
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0954-6111/01/060437+07 $35?00/0Materials and methods
IDENTIFICATION OF TRIALS
We sought to identify all relevant RCTs in adult patients with
hypoxaemia and COPD, chronic airflow limitation (CAL),
chronic obstructive airways disease (COAD) or chronic
airflow obstruction (CAO) that compared long-term dom-
iciliary or home oxygen therapy with a control group. The
intervention in the active treatment group covered all forms
of LTOT, including provision of oxygen using cylinders,
concentrators or liquid oxygen therapy. In the control group,
the intervention was either placebo air by the same method of
delivery or no specific intervention. The majority of the
patients had chronic hypoxaemia, an arterial oxygen tension
(PaO2)555mmHg (7?3kPa), but some of the patients had a
PaO2455mmHg (7?3kPa) at rest with evidence of nocturnal
hypoxaemia or desaturation with exercise.
SEARCH STRATEGY
Trials were identified with assistance from the Cochrane
Airways Group, London, U.K. using the Cochrane# 2001 HARCOURT PUBLISHERS LTD
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or domiciliary and oxygen. This register is regularly
updated by electronic searches and hand searches of
relevant journals. Following this, the bibliographies of
each RCT were searched for additional papers that may
have contained RCTs. Authors of identified RCTs were
contacted for additional data. In addition, companies who
supply the oxygen delivery devices and members of the
International Respiratory Care Association were contacted
for unpublished studies.
Two reviewers assessed all RCTs that appeared potentially
relevant, and then independently selected the trials for
inclusion in this review. Disagreement was resolved by
consensus. The trials were rated for the quality of allocation
concealment according to the method proposed by Schulz (2).
OUTCOME MEASURES
The outcome measures determined in advance for the
review were:
. Survival from the commencement of home oxygen
therapy as measured by all cause mortality.
. Health related quality of life as measured by a
validated instrument.
. Improvement in physiological parameters.
DATA EXTRACTION, ANALYSIS AND
STATISTICAL METHODS
Two reviewers, using a standard form, extracted data on
the types of study, participants, methodology, interventions
and outcomes. Subgroup analysis included, where possible,
a comparison of:
(1) Male with female patients;
(2) Continuous oxygen therapy versus nocturnal oxygen
therapy;
(3) Oxygen therapy versus no oxygen therapy;
(4) Nocturnal oxygen therapy versus room air for arterial
oxygen desaturation during sleep;
(5) Long-term oxygen therapy versus no oxygen therapy
for moderate hypoxaemia.
RevMan 4?0 statistical software provided by the Cochrane
Collaboration was used in the analysis (3). We calculated
Peto odds ratios with 95% confidence interval (95% CI)
using a fixed effects model on an intention to treat basis.
Results
Seven abstracts were identified from the comprehensive
searches of the databases. The full text was obtained for all
of the abstracts (4–10). Three papers were found to be
reports on various aspects of one RCT (Nocturnal Oxygen
Therapy Trial; NOTT) (4–6). One of these was excluded as
it contained baseline data only (5). The physiological data
from another of these papers were combined with data
from the original NOTT study report (6). Five RCTs wereconsidered suitable for inclusion in the review (4,7–10).
Table 1 summarizes these trials and includes the number of
participants, the intervention and the control regime. The
trials are described in more detail below. No additional
data could be obtained from the authors of the studies.
Two studies (7,9) treated subjects with COPD with
long-term oxygen therapy versus no oxygen therapy.
However, these two studies were not combined as the
MRC study included subjects with severe hypoxaemia
(PaO2, 40–60mmHg, 5?3–8?0 kPa) while the study by
Go´recka et al. included subjects with moderate hypoxaemia
(PaO2 56–65mmHg, 7?4–8?7 kPa). Although both studies
included a small number of female subjects, survival was
stratified by gender for the MRC study but not for study by
Go´recka et al.
Data from the two studies of nocturnal oxygen therapy
in patients with COPD and mild to moderate hypoxaemia
were combined (8,10).
Four of the trials were scored as having adequate
concealment. One trial described the method of randomiza-
tion as ‘blind draw’ with the vendor and respiratory
therapist knowing the treatment code and so was given a
rating of unclear concealment (8).
NOTT STUDY
A total of 1043 patients from six centres in North America
were screened for inclusion in the Nocturnal Oxygen
Therapy Trial (NOTT) (4). Eight hundred and nine patients
were excluded for a variety of reasons including other
major concomitant disease, refusal to participate or because
patients were already using oxygen therapy or had a PaO2
greater than 59mmHg (7?9 kPa). The study was not
blinded. Two hundred and three patients with hypoxaemic
chronic obstructive lung disease were randomly allocated to
nocturnal oxygen therapy (n102) or continuous oxygen
therapy (n101) at a flow-rate of 1–4 lmin71. The oxygen
source was an oxygen concentrator, liquid oxygen or
compressed gas. The mean age was 65?7 years in the
nocturnal oxygen therapy group and 65?2 years in the
continuous oxygen therapy group. Most patients were
male: 80?4% in the nocturnal oxygen therapy group and
77?2% in the continuous oxygen therapy group. Mean
baseline forced expiratory volume in 1 sec (FEV1) was
29?9% predicted for the nocturnal oxygen therapy group
and 29?5% predicted for the continuous oxygen therapy
group. Mean baseline PaO2 was 51?5mmHg (nocturnal
group) and 50?8mmHg for the continuous oxygen therapy
group.
Figure 1 shows the odds ratios for each of the treatment
categories by trial included in this meta-analysis. For the
NOTT study the survival at 12 months was not significant
(Peto odds ratio 0?53; 95% CI: 0?25–1?11). At 24 months
there was a significant improvement in mortality for the
continuous oxygen treatment group (Peto odds ratio 0?45;
95% CI: 0?25–0?81).
In this RCT, quality of life parameters and several
physiological variables were studied, but the number of
patients in each group was not defined and could not be
TABLE 1. Table of included studies
Trial No. of
patients
Treatment groups Treatment Control
NOTT (4) 203 101 patients (77?2% male)
received continuous
oxygen therapy and 102
patients (80?4%) male
received nocturnal
oxygen therapy
1–4 lmin71 by concentrator,
liquid oxygen or
compressed gas
Mean of 12 h day71
nocturnal oxygen therapy
MRC (7) 87 66 males (33 treated and
33 controls) and 21 females
(9 treated and 12
controls) were included
in the trial
Domiciliary oxygen therapy
(at least 15 h day71, at
least 2 lmin71) by
concentrator, cylinder or liquid
oxygen. Flow rate adjusted to
raise PaO2 above 60mmHg
No oxygen therapy
Fletcher
et al. (8)
38 19 patients were sham-treated,
19 patients were treated with
oxygen therapy (gender
not given)
Oxygen therapy at 3 lmin71
was administered during
sleep versus compressed
air at 3 lmin71
Treatment with compressed
air with an oxygen
concentration no greater
than 25%
Go´recka
et al. (9)
135 103 males (51 treated and
52 controls) and 32 females
(17 treated and 15 controls)
and included in the trial
Patients treated with
long-term oxygen
therapy received concentrator
oxygen adjusted to raise
PaO2 above 65mmHg (8?7 kPa)
No oxygen therapy
Chaouat
et al. (10)
76 41 patients received nocturnal
oxygen therapy 35 no oxygen
therapy, gender not given
Concentrator oxygen therapy
at usually 2 lmin71 for
8–10 h at night
No oxygen therapy
PaO2: arterial oxygen tension.
FIG. 1. Quantitative effects of domiciliary oxygen on survival in COPD.
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440 A. J. CROCKETT ET AL.assessed using this meta-analysis protocol. Timm’s paper
on the NOTT study reported no significant difference
between the treated and nocturnal groups of patients for
the physiological parameters right atrial pressure, pulmon-
ary capillary wedge pressure, cardiac index and right
ventricular stroke work index. However, the continuous
oxygen therapy group was reported to show improvement
in stroke volume index, pulmonary vascular resistance and
pulmonary artery pressure.
The study speculated that those patients most likely to
benefit from continuous oxygen therapy would have
relatively severely impaired quality of life and brain
dysfunction but relatively mild disturbances of pulmonary
haemodynamics and exercise capacity.
MRC TRIAL
The Medical Research Council (MRC) trial of long-term
domiciliary oxygen therapy took place in three centres in
the U.K. (7). The patients had a diagnosis of chronic
bronchitis and emphysema, and were randomized to receive
oxygen therapy or no oxygen (controls). The study was not
blinded. Patients were enrolled in the study if they had a
PaO2 of between 40 and 60mmHg (5?3 and 8 kPa) and one
or more recorded episodes of heart failure with ankle
oedema, and so were highly selected. Thirty-three men
and nine women received oxygen therapy for at least
15 h day71 at a flow rate of a minimum of 2 lmin71. Eight
subjects received liquid oxygen therapy and all but one of
the patients (total number not disclosed) in one centre
received oxygen via an oxygen concentrator. The remaining
subjects received oxygen from cylinders. A total of 33 men
and 12 women formed the control group.
Mean (range) age was 58?2 (44–69) years for the male
treated group, 56?2 (42–68) years for the male control
group, 59?4 (55–67) years for the female treated group and
59?3 (50–69) years for the female controls. Mean baseline
FEV1 was 0?76 l and 0?58 l for the treated male and female
groups and 0?65 l and 0?63 l for the control male and female
groups. Mean baseline forced vital capacity (FVC) was
1?92 l and 1?31 l for the treated male and female groups and
1?88 l and 1?46 l for the control male and female groups.
Mean baseline PaO2 was 50?4mmHg (6?7 kPa) and
49?4mmHg (6?6 kPa) for the treated male and female
groups, and 51?5mmHg (6?9 kPa) and 51?8mmHg
(6?9 kPa) for the control male and female groups.
There was an improvement over 5 years in mortality in
the group receiving oxygen therapy (Peto odds ratio 0?42,
95% Cl: 0?18–0?98) as shown in Fig. 1. However, there was
no difference in mortality for male patients in both treated
and control groups up to 500 days from commencement of
treatment. In female patients, mortality was improved for
the oxygen-treated group from the commencement of
treatment. However, the number of female patients in each
of the treated and control groups was small (n9 and n12,
respectively).
Physiological variables could not be assessed using this
meta-analysis protocol. The study found that the male
subjects most likely to benefit from oxygen therapy had a
sum of the red cell mass and PaCO2 less than 98.FLETCHER STUDY
Thirty-eight subjects with COPD, a daytime
PaO2460mmHg and nocturnal sleep desaturation agreed
to participate in the Fletcher double-blind RCT and were
randomized into the study (8). An additional 13 patients
with similar baseline pulmonary function who did not
desaturate were also followed up but not randomized. In
the ‘sham-treated’ group of 19 patients, six died and four
were excluded (two withdrew, one developed daytime
hypoxaemia, one was non-compliant). Of the original 19
treated subjects, six developed significant daytime hypo-
xaemia, one developed worsening of sleep apnoea and there
were five deaths.
Oxygen was supplied in the active group by an oxygen
concentrator. The control group received gas from an
oxygen concentrator rendered ineffective. However, some
control group patients received an oxygen concentration of
25% rather than the ambient concentration of 21%,
equivalent to an inspired oxygen tension of approximately
30mmHg (4 kPa) greater than if they had received room
air. Mean age in the control group was 61?2 years and mean
age in the oxygen-treated group was 62?1 years. The gender
of the subjects was not given.
Physiological parameters could not be assessed using this
meta-analysis protocol.
There was no difference in mortality after 36 months
between the oxygen-treated and sham-treated groups.
However, the possibility of a type 2 error occurring could
not be rejected due to the small study size even though the
point estimate of mortality was very close to the odds ratio
of 1?0.
GO´RECKA STUDY
One hundred and thirty-five patients with COPD and
moderate hypoxaemia referred to nine regional centres in
Poland were included in the unblinded RCT (9). Patients
with concomitant disease that might impact on survival
were excluded from the study.
Sixty-seven patients (52 males, 15 females, mean age 62?4
years) formed the control group and 68 patients (51 males
17 females, mean age 60?1 years), formed the treatment
group. Both treated and control groups received ‘usual
treatment’ which consisted of bronchodilators, antibiotics,
corticosteroids and diuretics as required. The oxygen group
were prescribed at least 17 h of oxygen per day from an
oxygen concentrator at a flow rate that raised their resting
PaO2 greater than 8?7 kPa (65mmHg). This group used a
mean of 13?5 h of oxygen therapy per day. The patients
were followed for 3 years or until death.
No difference in mortality during the study period was
found between COPD patients with moderate hypoxaemia
under conventional treatment plus long-term oxygen
therapy versus conventional treatment only. In the inter-
vention group, duration of oxygen therapy (over 15 h
day71) did not affect survival.
Physiological parameters could not be assessed because
these were not reported by treatment group.
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Seventy-six patients with COPD and mild to moderate
daytime hypoxaemia, PaO2 56–69mmHg (7?4–9?2 kPa)
exhibiting significant nocturnal desaturation were rando-
mized into this unblinded study (10). The patients were
recruited from six hospital outpatient clinics of four
European countries.
Thirty-five patients, mean age 64+6 years, gender not
defined, formed the control group and 41 patients, mean
age 63+8 years the treatment group. Patients were
excluded if they had a variety of co-morbidities including
left heart or congenital heart disease, interstitial lung
disease, bronchiectasis, lung carcinoma or other severe
disease that could influence survival. Patients with ob-
structive sleep apnoea were also excluded. Patients in the
treatment group were given concentrator oxygen for 8–10 h
per night at a flow rate usually of 2 lmin71. The control
group received no oxygen therapy. There was no difference
in mortality between the treated and control groups on an
intention to treat basis.
Nocturnal oxygen did not allow delay in the prescription
of long-term oxygen therapy. Twelve patients in the
nocturnal oxygen group and 10 control group patients
deteriorated and required treatment with conventional
long-term oxygen therapy during the follow-up period of
from 2?5 to 60 months. Five of these patients subsequently
died, two in the treated group and three in the control
group.
Pulmonary haemodynamic parameters could not be
assessed due to limitations in the meta-analysis protocol.
However, no significant difference between treated and
control groups in the evolution of any of these parameters
was reported over a 2-year period.
There was no difference in mortality between the treated
and control groups when the Chaouat and Fletcher data
were aggregated, with the summary Peto odds ratio moving
close to unity than the individual odds ratios (0?97, 95%
CI: 0?41–2?31).
Discussion
SURVIVAL
Two of the five RCTs included in this review demonstrated
a significant survival advantage for the selected COPD
subjects receiving long-term oxygen therapy (4,7). In the
NOTT study there was a significant improvement in
mortality for hypoxaemic COPD patients after 24 months
of treatment with continuous long-term oxygen therapy
when compared to the nocturnal oxygen therapy group. In
the MRC study long-term oxygen therapy produced a small
but significant overall improvement in survival in both male
and female patients with severe hypoxic cor pulmonale
complicating chronic bronchitis and emphysema. However,
the authors reported a different survival response between
males and females. Survival for treated and control male
patients was similar until 500 days from the commencement
of treatment probably due to small numbers and inade-quate resolution. However, the mortality of the control
female patients was reported to be significantly greater than
that of the treated females from the commencement of
home oxygen therapy.
A number-needed-to-treat estimate (1/absolute risk
reduction) of 4?5 can be calculated for the MRC study
where the risk of death in the control group is 0?67, the risk
of death for the oxygen group is 0?45 and the absolute risk
reduction is 0?22. Thus, for the MRC study, five patients
with severe hypoxaemic COPD with long-term oxygen
therapy needed to be treated to save one life over the 5-year
study period.
Nocturnal supplemental oxygen for COPD patients with
nocturnal sleep desaturation but mild to moderate daytime
hypoxaemia did not improve mortality. Nocturnal oxygen
therapy did not delay the requirement for long-term oxygen
therapy, which was similar in both the treated and control
group patients for the Chaouat study. In the Fletcher study
one sham group patient and six patients in the treatment
group developed daytime hypoxaemia. The number of
patients included in the Chaouat study was too small to
determine if the cross-over to long-term oxygen therapy
had an effect on survival.
Supplemental oxygen therapy for COPD patients with
moderate hypoxaemia (9) did not prolong survival.
The relatively small numbers of patients, their young age
and their lack of co-morbidities in most of the above studies
raise concerns about the applicability of the survival
outcomes to current clinical situations. Unselected patients
with COPD fulfilling prescription guidelines for domiciliary
oxygen therapy appear to be older than the subjects
included in these studies and the majority of them have
multiple co-morbidities (11). The assumption that home
oxygen therapy has a beneficial effect in these patients has
not been tested.
QUALITY OF LIFE ISSUES
Quality of life and other health outcome variables such as
physiological parameters could not be included in this
review due to limitations in the available software at this
point in time. The Chaouat study concluded that nocturnal
oxygen therapy in patients with COPD and mild to
moderate daytime hypoxaemia did not modify the evolu-
tion of pulmonary haemodynamics. This was in contrast to
the Fletcher study where it was reported that nocturnal
oxygen therapy resulted in improved haemo-
dynamics. However, the number of patients included in
the Fletcher study was small.
Physiological variables should be considered intermedi-
ate outcomes, while survival and quality of life should be
considered as the more definitive outcomes. It is possible
that statistically significant improvement in some physio-
logical variables may have little measurable impact on the
subjects’ perceived quality of life or survival.
The MRC study reported that indicators such as general
improvement in the sense of well being, improved appetite,
and general alertness were frequently found in those
patients treated with oxygen therapy (7). However, no data
442 A. J. CROCKETT ET AL.were given. The NOTT study reported neuropsychological
deficits in hypoxic COPD patient groups and observed
small improvements in neuropsychological function and
quality of life when data from all patients were combined
(4,5).
LIMITATIONS OF THE STUDIES
This systematic review has highlighted several problems
with patient selection and study design. Only one of the
studies was double-blinded due to the inability to blind
liquid oxygen therapy (8). The treatment regime for the
control groups of the studies varied from none for the
Go´recka study, to nocturnal oxygen therapy for the NOTT
study, to sham treatment through a disabled oxygen
concentrator equivalent to 25% oxygen therapy in the
Fletcher study. In the Fletcher study this level of oxygen
therapy for the control subjects may have confounded the
results as this higher oxygen tension may have been
reflected in the PaO2 in this group. The control group in
the MRC study did not receive a sham treatment regime.
In the NOTT study the numbers of patients receiving the
different modes of oxygen treatment were not given. There
were some differences between treatment and control
groups at baseline in the MRC study. Females in the
treated group appeared to have more compromised lung
function than those of the control group, while the reverse
appeared to be apparent for the male patient groups. The
mean number of hospitalizations and hospitalized days in
the Fletcher study could not be included in this review as
standard deviations were not given. The Go´recka study
reported differences in studied variables by survivors and
non-survivors.
No data were reported in the two major studies (NOTT
and MRC) about the effects of continuing or ceasing
smoking or indeed if smoking status affected the outcomes.
The mean arterial CO2 tension at baseline was higher in the
MRC study than in the NOTT study. This did not appear
to influence the results. Other known prognostic indicators
such as body mass index were not discussed in either of the
studies. The lack of exacerbation data is also a further
limiting factor in interpreting the results.
IMPLICATIONS FOR RESEARCH
The role of long-term oxygen therapy prescribed for a
longer time period (at least 19 h day71) in COPD with
moderate hypoxaemia and/or nocturnal desaturation re-
quires further investigation, with larger numbers of
participants included in the studies.
Ethical concerns have been raised about the randomiza-
tion of patients to placebo and this may be a barrier to
obtaining more appropriate health status data about the
effects of oxygen in more severely hypoxaemic subjects.
Further development of the Revman software package is
required to enable more comprehensive comparisons of the
available data.Conclusions
Long-term oxygen therapy improved survival in a selected
group of COPD patients with severe hypoxaemia but few
co-morbidities. Although many physiological outcomes
were measured in the NOTT and MRC trials, none clearly
indicated a plausible mechanism for the effect on mortality.
Long-term oxygen therapy did not appear to improve
survival in patients with COPD and moderate hypoxaemia
nor in COPD patients with nocturnal desaturation but
resting daytime oxygenation above that to qualify for
oxygen therapy.
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